
Response Criteria and PRRT Treatment
Through her 2021 NETRF Investigator Award, Lisa Bodei, MD, PhD, professor of radiology at Weill Cornell Medical College, attending physician and director of targeted radionuclide
Make a gift before the end of the year to drive research breakthroughs in 2026.

Through her 2021 NETRF Investigator Award, Lisa Bodei, MD, PhD, professor of radiology at Weill Cornell Medical College, attending physician and director of targeted radionuclide

United States Congressman Joaquin Castro (TX) joined the NET community in Austin, Texas on September 23rd and shared, for the first time publicly, his personal

NETRF, in partnership with the North American Neuroendocrine Tumor Society (NANETS), is pleased to announce that Iacovos Michael, PhD, Scientist at Sunnybrook Research Institute and

Positive results are reported from the Phase 3 CABINET trial evaluating the drug cabozantinib in advanced neuroendocrine tumors. Interim data shows significant improvement in progression-free

In December 2022, four neighborhood girls from Libertyville, Il, gathered to support cancer research for the Neuroendocrine Tumor Research Foundation with a “Cookies for Cancer”

NETRF’s impact on neuroendocrine cancer research was evident at the 20th Annual European Neuroendocrine Tumor Society (ENETS) Conference, held March 22-24 in Vienna. The ENETS

A key tenet of NETRF’s mission is to help NET patients navigate the challenges of living with NET cancer. Participating in a clinical trial can

We are very grateful to Buckeye Cable Arts Network for allowing us to promote and share this wonderful story reporter Fayth Atkins produced about NET

BE HEARD: Share your story with staff of the FDA about your experience or your loved one’s living with #CarcinoidSyndrome (CS). #FDA’s Patient Affairs and NORD are hosting

NET patient, oncologist, and NETRF Board Member Mark Lewis, MD, is a native Scotsman who moved to Austin, TX as a young man when his